{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:18:02Z","timestamp":1783181882339,"version":"3.54.6"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100030831","name":"Novartis Pharma K.K.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030831","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12325-025-03321-5","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T12:31:45Z","timestamp":1753965105000},"page":"4933-4949","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Preferences for Injectable Lipid-Lowering Therapies in Japanese Patients with Atherosclerotic Cardiovascular Disease: Findings from a Japanese Cross-sectional Study"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5709-5598","authenticated-orcid":false,"given":"Mitsutoshi","family":"Toda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Iekushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Kohsaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"3321_CR1","unstructured":"Country Profiles: Japan (2019). In: Institute for Health Metrics and Evaluation [Internet]. 2019 [cited 25 Jun 2024]. Available from: https:\/\/www.healthdata.org\/research-analysis\/health-by-location\/profiles\/japan"},{"key":"3321_CR2","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41569-024-01039-5","volume":"21","author":"BA Ference","year":"2024","unstructured":"Ference BA, Braunwald E, Catapano AL. The LDL cumulative exposure hypothesis: evidence and practical applications. Nat Rev Cardiol. 2024;21:701\u201316. https:\/\/doi.org\/10.1038\/s41569-024-01039-5.","journal-title":"Nat Rev Cardiol"},{"key":"3321_CR3","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1093\/eurheartj\/ehab841","volume":"43","author":"L Tokg\u00f6zo\u011flu","year":"2022","unstructured":"Tokg\u00f6zo\u011flu L, Libby P. The dawn of a new era of targeted lipid-lowering therapies. Eur Heart J. 2022;43:3198\u2013208. https:\/\/doi.org\/10.1093\/eurheartj\/ehab841.","journal-title":"Eur Heart J"},{"key":"3321_CR4","doi-asserted-by":"publisher","first-page":"641","DOI":"10.5551\/jat.GL2022","volume":"31","author":"T Okamura","year":"2024","unstructured":"Okamura T, Tsukamoto K, Arai H, et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022. J Atheroscler Thromb. 2024;31:641\u2013853. https:\/\/doi.org\/10.5551\/jat.GL2022.","journal-title":"J Atheroscler Thromb"},{"key":"3321_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12944-020-01297-5","volume":"19","author":"W Masson","year":"2020","unstructured":"Masson W, Lobo M, Siniawski D, et al. Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression. Lipids Health Dis. 2020;19:111. https:\/\/doi.org\/10.1186\/s12944-020-01297-5.","journal-title":"Lipids Health Dis"},{"key":"3321_CR6","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1253\/circj.CJ-21-1041","volume":"86","author":"S Nakano","year":"2022","unstructured":"Nakano S, Kohsaka S, Chikamori T, et al. JCS 2022 guideline focused update on diagnosis and treatment in patients with stable coronary artery disease. Circ J. 2022;86:882\u2013915. https:\/\/doi.org\/10.1253\/circj.CJ-21-1041.","journal-title":"Circ J"},{"key":"3321_CR7","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","volume":"148","author":"SS Virani","year":"2023","unstructured":"Virani SS, Newby LK, Arnold SV, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American heart association\/American college of cardiology joint committee on clinical practice guidelines. Circulation. 2023;148:e9\u2013119. https:\/\/doi.org\/10.1161\/CIR.0000000000001168.","journal-title":"Circulation"},{"key":"3321_CR8","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720\u2013826. https:\/\/doi.org\/10.1093\/eurheartj\/ehad191.","journal-title":"Eur Heart J"},{"key":"3321_CR9","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1253\/circj.CJ-23-0814","volume":"88","author":"F Sheng","year":"2024","unstructured":"Sheng F, Wang AY, Miyawaki K, et al. Real-world clinical profile of patients prescribed evolocumab in Japan. Circ J. 2024;88:1629\u201336. https:\/\/doi.org\/10.1253\/circj.CJ-23-0814.","journal-title":"Circ J"},{"key":"3321_CR10","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.5551\/jat.63940","volume":"30","author":"H Mitani","year":"2023","unstructured":"Mitani H, Suzuki K, Ako J, et al. Achievement rates for low-density lipoprotein cholesterol goals in patients at high risk of atherosclerotic cardiovascular disease in a real-world setting in Japan. J Atheroscler Thromb. 2023;30:1622\u201334. https:\/\/doi.org\/10.5551\/jat.63940.","journal-title":"J Atheroscler Thromb"},{"key":"3321_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100624","volume":"29","author":"KK Ray","year":"2023","unstructured":"Ray KK, Haq I, Bilitou A, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health - Eur. 2023;29: 100624. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100624.","journal-title":"Lancet Reg Health - Eur"},{"key":"3321_CR12","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227\u2013337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484.","journal-title":"Eur Heart J"},{"key":"3321_CR13","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1161\/CIR.0000000000000678","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines. Circulation. 2019;140:e596\u2013646. https:\/\/doi.org\/10.1161\/CIR.0000000000000678.","journal-title":"Circulation"},{"key":"3321_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/hex.14043","volume":"27","author":"L Zhang","year":"2024","unstructured":"Zhang L, Chen J, Cao Z, et al. Patient versus physician preferences for lipid-lowering drug therapy: a discrete choice experiment. Health Expect. 2024;27: e14043. https:\/\/doi.org\/10.1111\/hex.14043.","journal-title":"Health Expect"},{"key":"3321_CR15","doi-asserted-by":"publisher","first-page":"876","DOI":"10.5551\/jat.64454","volume":"31","author":"S Yamashita","year":"2024","unstructured":"Yamashita S, Kiyosue A, Maheux P, et al. Efficacy, safety, and pharmacokinetics of inclisiran in Japanese patients: results from ORION-15. J Atheroscler Thromb. 2024;31:876\u2013903. https:\/\/doi.org\/10.5551\/jat.64454.","journal-title":"J Atheroscler Thromb"},{"key":"3321_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.amjcard.2015.10.021","volume":"117","author":"A Kiyosue","year":"2016","unstructured":"Kiyosue A, Honarpour N, Kurtz C, Xue A, Wasserman SM, Hirayama A. A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk. Am J Cardiol. 2016;117:40\u20137. https:\/\/doi.org\/10.1016\/j.amjcard.2015.10.021.","journal-title":"Am J Cardiol"},{"key":"3321_CR17","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1161\/CIRCULATIONAHA.119.043406","volume":"141","author":"J Brandts","year":"2020","unstructured":"Brandts J, Ray KK. Low density lipoprotein cholesterol\u2013lowering strategies and population health: time to move to a cumulative exposure model. Circulation. 2020;141:873\u20136. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.043406.","journal-title":"Circulation"},{"key":"3321_CR18","doi-asserted-by":"publisher","unstructured":"Krychtiuk KA, Ahrens I, Drexel H, et al. Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. 2022; 11:939\u2013949. https:\/\/doi.org\/10.1093\/ehjacc\/zuac123","DOI":"10.1093\/ehjacc\/zuac123"},{"key":"3321_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1186\/s12872-024-04321-z","volume":"24","author":"S Zhang","year":"2024","unstructured":"Zhang S, Sun L, Xu X, Zhang Y, Chen Q. Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis. BMC Cardiovasc Disord. 2024;24:629. https:\/\/doi.org\/10.1186\/s12872-024-04321-z.","journal-title":"BMC Cardiovasc Disord"},{"key":"3321_CR20","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1253\/circj.CJ-16-1016","volume":"81","author":"A Hirayama","year":"2017","unstructured":"Hirayama A, Yamashita S, Inomata H, et al. One-year efficacy and safety of evolocumab in Japanese patients - a pooled analysis from the open-label extension OSLER studies -. Circ J. 2017;81:1029\u201335. https:\/\/doi.org\/10.1253\/circj.CJ-16-1016.","journal-title":"Circ J"},{"key":"3321_CR21","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ypmed.2011.02.019","volume":"52","author":"H Imano","year":"2011","unstructured":"Imano H, Noda H, Kitamura A, et al. Low-density lipoprotein cholesterol and risk of coronary heart disease among Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). Prev Med. 2011;52:381\u20136. https:\/\/doi.org\/10.1016\/j.ypmed.2011.02.019.","journal-title":"Prev Med"},{"key":"3321_CR22","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1253\/circj.CJ-17-0033","volume":"81","author":"M Ishihara","year":"2017","unstructured":"Ishihara M, Nakao K, Ozaki Y, et al. Long-term outcomes of non-ST-elevation myocardial infarction without creatine kinase elevation - The J-MINUET study -. Circ J. 2017;81:958\u201365. https:\/\/doi.org\/10.1253\/circj.CJ-17-0033.","journal-title":"Circ J"},{"key":"3321_CR23","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s40120-024-00663-0","volume":"13","author":"T Takeshima","year":"2024","unstructured":"Takeshima T, Yuasa A, Lloyd YM, et al. A discrete-choice experiment assessing the patient preferences and real-world experiences of patients with migraine in Japan. Neurol Ther. 2024;13:1661\u201383. https:\/\/doi.org\/10.1007\/s40120-024-00663-0.","journal-title":"Neurol Ther"},{"key":"3321_CR24","doi-asserted-by":"publisher","DOI":"10.2196\/50193","volume":"7","author":"Y He","year":"2023","unstructured":"He Y, Matsunaga M, Li Y, et al. Classifying schizophrenia cases by artificial neural network using Japanese web-based survey data: case-control study. JMIR Form Res. 2023;7: e50193. https:\/\/doi.org\/10.2196\/50193.","journal-title":"JMIR Form Res"},{"key":"3321_CR25","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1007\/s12325-021-01810-x","volume":"38","author":"T Deguchi","year":"2021","unstructured":"Deguchi T, Takatsuna H, Yokoyama M, et al. A cross-sectional web survey of satisfaction with treatment for pain in participants with suspected diabetic peripheral neuropathic pain in both feet. Adv Ther. 2021;38:4304\u201320. https:\/\/doi.org\/10.1007\/s12325-021-01810-x.","journal-title":"Adv Ther"},{"key":"3321_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.70042","volume":"8","author":"T Ota","year":"2024","unstructured":"Ota T, Kuratani S, Masaki H, Ishizaki S, Seki H, Takebe T. Impact of chronic constipation symptoms on work productivity and daily activity: a large-scale internet survey. JGH Open. 2024;8: e70042. https:\/\/doi.org\/10.1002\/jgh3.70042.","journal-title":"JGH Open"},{"key":"3321_CR27","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s13300-024-01584-9","volume":"15","author":"H Ishii","year":"2024","unstructured":"Ishii H, Maeda Y, Sato M, Cai Z, Imori M. Therapy-related satisfaction and quality of life for Japanese people with diabetes using rapid-acting insulin analogs: a web-based survey. Diabetes Ther. 2024;15:1577\u201395. https:\/\/doi.org\/10.1007\/s13300-024-01584-9.","journal-title":"Diabetes Ther"},{"key":"3321_CR28","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.035809","volume":"13","author":"K Yokote","year":"2024","unstructured":"Yokote K, Ako J, Kitagawa K, et al. Safety and effectiveness of low-density lipoprotein cholesterol-lowering therapy with evolocumab for familial hypercholesterolemia\/hypercholesterolemia in Japan: a real-world, postmarketing, single-arm study. J Am Heart Assoc. 2024;13: e035809. https:\/\/doi.org\/10.1161\/JAHA.124.035809.","journal-title":"J Am Heart Assoc"},{"key":"3321_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JFP Bridges","year":"2011","unstructured":"Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14:403\u201313. https:\/\/doi.org\/10.1016\/j.jval.2010.11.013.","journal-title":"Value Health"},{"key":"3321_CR30","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, Gonz\u00e1lez JM, Groothuis-Oudshoorn CGM, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19:300\u201315. https:\/\/doi.org\/10.1016\/j.jval.2016.04.004.","journal-title":"Value Health"},{"key":"3321_CR31","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/hec.1197","volume":"16","author":"AR Hole","year":"2007","unstructured":"Hole AR. A comparison of approaches to estimating confidence intervals for willingness to pay measures. Health Econ. 2007;16:827\u201340. https:\/\/doi.org\/10.1002\/hec.1197.","journal-title":"Health Econ"},{"key":"3321_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-024-00705-7","author":"FR Johnson","year":"2024","unstructured":"Johnson FR, Adamowicz W, Groothuis-Oudshoorn C. What can discrete-choice experiments tell us about patient preferences? An introduction to quantitative analysis of choice data. The Patient. 2024. https:\/\/doi.org\/10.1007\/s40271-024-00705-7.","journal-title":"The Patient"},{"key":"3321_CR33","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.3390\/jcm11154611","volume":"11","author":"R Rikhi","year":"2022","unstructured":"Rikhi R, Shapiro MD. Newer and emerging LDL-C lowering agents and implications for ASCVD residual risk. J Clin Med. 2022;11:4611. https:\/\/doi.org\/10.3390\/jcm11154611.","journal-title":"J Clin Med"},{"key":"3321_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2021-001931","volume":"9","author":"R Khatib","year":"2022","unstructured":"Khatib R, Khan M, Barrowcliff A, et al. Innovative, centralised, multidisciplinary medicines optimisation clinic for PCSK9 inhibitors. Open Heart. 2022;9: e001931. https:\/\/doi.org\/10.1136\/openhrt-2021-001931.","journal-title":"Open Heart"},{"key":"3321_CR35","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/dom.14244","volume":"23","author":"K Boye","year":"2021","unstructured":"Boye K, Ross M, Mody R, Konig M, Gelhorn H. Patients\u2019 preferences for once-daily oral versus once-weekly injectable diabetes medications: the REVISE study. Diabetes Obes Metab. 2021;23:508\u201319. https:\/\/doi.org\/10.1111\/dom.14244.","journal-title":"Diabetes Obes Metab"},{"key":"3321_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-024-08377-7","volume":"32","author":"MS Khan","year":"2024","unstructured":"Khan MS, Cook K, Weickert MO, et al. PREF-NET: a patient preference and experience study of lanreotide autogel administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumours in the UK. Support Care Cancer. 2024;32: 199. https:\/\/doi.org\/10.1007\/s00520-024-08377-7.","journal-title":"Support Care Cancer"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03321-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03321-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03321-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:09:20Z","timestamp":1758899360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03321-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3321"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03321-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Novartis Pharma K.K. Mitsutoshi Toda, Yuri Takahashi, Kazuma Iekushi are employees of Novartis Pharma K.K. Shun Kohsaka has received research funding from the Japan Society for the Promotion of Science, and has received consulting fees from Pfizer, outside of the submitted work. Data acquisition, statistical analysis, and drafting of the manuscript were performed by Social Survey Research Information Co., Ltd., funded by Novartis Pharma K.K.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved by Kitamachi Clinic Ethical Review Committee of the Medical Corporation Tokeikai. The approval number was BGQ09833. The approval date was January 17, 2024. The study complied with the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects (Ministry of Health, Labour and Welfare of Japan).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}